Low-Dose Naltrexone Cost in Indiana (2026): Cash Prices, Insurance, and Savings

What Does Low-Dose Naltrexone Actually Cost in Indiana?

The average cash-pay price for compounded LDN across Indiana pharmacies in 2026 is approximately $50 per month for a standard 1.5 mg to 4.5 mg oral capsule supply. This figure reflects pricing from licensed 503A compounding pharmacies, which are the primary source of LDN in the state, since no manufacturer produces a commercially available tablet at low-dose strengths.

Price variation does exist. Some Indiana compounding pharmacies charge as little as $35 per month for a 30-day supply of 4.5 mg capsules, while others charge up to $75 depending on the formulation, dose, and whether the pharmacy offers a subscription model. Liquid formulations, which allow more precise dose titration during the initial ramp-up period, sometimes cost $5 to $15 more per month than capsules.

For context, the FDA-approved 50 mg naltrexone tablet (brand name ReVia) carries an average retail price of roughly $45 to $90 per month at Indiana chain pharmacies according to 2026 GoodRx estimates. Some patients and prescribers have historically used pill-splitting or dissolving techniques with 50 mg tablets to approximate low doses. This practice is unreliable for achieving consistent sub-milligram accuracy and is not recommended by compounding pharmacists or the FDA's guidance on drug compounding.

The $50 per month cash-pay figure makes LDN one of the more affordable off-label options in the pain and autoimmune space. By comparison, branded biologics for autoimmune conditions commonly exceed $3,000 per month before insurance, and even generic immunosuppressants like azathioprine run $30 to $80 monthly. The cost barrier for LDN in Indiana is less about the drug itself and more about the prescriber visit, which we address below.

Does Indiana Medicaid Cover Low-Dose Naltrexone?

No. Indiana Medicaid does not cover naltrexone at low doses for off-label indications such as fibromyalgia, Crohn's disease, or autoimmune conditions. Medicaid coverage in Indiana applies only to FDA-approved indications for naltrexone, which means the 50 mg formulation for opioid use disorder or alcohol dependence.

This coverage gap exists because LDN is prescribed off-label. The FDA's approved labeling for naltrexone lists only opioid antagonism at the 50 mg dose for substance use treatment. Since no manufacturer has pursued an FDA indication for low-dose naltrexone in pain or autoimmune conditions, state Medicaid formularies, including Indiana's, have no mechanism to adjudicate claims for compounded LDN.

Indiana's Medicaid managed care organizations (MCOs), including Anthem, CareSource, MDwise, MHS, and UnitedHealthcare Community Plan, follow the state formulary for outpatient drugs. A prior authorization request for LDN would require the prescriber to submit medical necessity documentation. In practice, these requests are routinely denied because compounded medications fall outside the standard Medicaid pharmacy benefit structure.

Patients enrolled in Indiana Medicaid who want to try LDN typically pay the $50 per month cash price directly to a compounding pharmacy. The prescriber visit may still be covered under Medicaid if the visit is coded for a covered diagnosis. This is an important distinction: the office visit and the prescription are billed separately, and Medicaid can cover the former even when it does not reimburse for the latter.

Is Compounded Low-Dose Naltrexone Legal in Indiana?

Compounded LDN is legal in Indiana when dispensed by a pharmacy operating under a valid 503A license. Section 503A of the Federal Food, Drug, and Cosmetic Act permits licensed pharmacies to compound medications for individual patients based on a valid prescription from a licensed prescriber. Indiana does not impose additional state-level restrictions on naltrexone compounding beyond federal requirements.

A 503A pharmacy must compound each prescription on a patient-specific basis. The pharmacist uses bulk pharmaceutical-grade naltrexone powder, measured and encapsulated to the exact milligram dose specified by the prescriber. This process is overseen by the Indiana Board of Pharmacy, which inspects and licenses all compounding facilities in the state.

The distinction between 503A and 503B matters here. 503B outsourcing facilities can produce compounded drugs in larger batches without patient-specific prescriptions, but they operate under more stringent FDA oversight. Most Indiana patients obtain LDN from 503A pharmacies because 503B facilities primarily supply hospitals and clinics rather than individual outpatients. Both pathways are legal.

Naltrexone itself is not a controlled substance under Indiana or federal law. It carries no DEA scheduling, which simplifies the prescribing and compounding process. Any Indiana-licensed physician, nurse practitioner, or physician assistant with prescriptive authority can write an LDN prescription. The drug does not require the special DEA waivers associated with buprenorphine or other scheduled medications.

Which Insurance Plans Cover LDN in Indiana?

Most commercial insurance plans in Indiana do not cover compounded LDN. The primary reason is straightforward: insurance pharmacy benefits are designed to reimburse for FDA-approved, commercially manufactured medications dispensed through contracted pharmacy networks. Compounded drugs generally fall outside these adjudication systems.

Specific Indiana market plans from Anthem Blue Cross Blue Shield, UnitedHealthcare, Cigna, Aetna, and the Indiana University Health Plans typically exclude compounded medications from their pharmacy formularies. A small number of employer-sponsored plans with more flexible pharmacy benefit designs may reimburse for compounded drugs, but this is uncommon. Patients should call the number on the back of their insurance card and ask specifically: "Does my pharmacy benefit cover compounded medications from a 503A pharmacy?"

There is one workaround that occasionally succeeds. If a prescriber writes for the commercially available naltrexone 50 mg tablet (brand ReVia or generic), insurance may cover that tablet. The patient then works with their pharmacist to discuss dosing. This approach has significant limitations in dose accuracy and is generally discouraged for the reasons noted above, but some patients and prescribers pursue it as a cost-reduction strategy when insurance is available for the 50 mg form.

Health savings accounts (HSAs) and flexible spending accounts (FSAs) can be used to pay for compounded LDN. Both the prescriber visit and the compounded prescription qualify as eligible medical expenses under IRS guidelines, provided the patient has a valid prescription. For Indiana residents on high-deductible health plans, HSA funds offer a tax-advantaged way to cover LDN costs.

How Telehealth Expands LDN Access Across Indiana

Indiana permits telehealth prescribing for LDN without geographic restriction. A patient in Evansville, Terre Haute, or any rural Indiana county can consult a licensed prescriber via video and receive an LDN prescription sent electronically to a compounding pharmacy.

This matters because LDN prescribing expertise is not evenly distributed. The drug's evidence base spans chronic pain, fibromyalgia, Crohn's disease, multiple sclerosis, and other conditions where its proposed mechanism of transient opioid receptor blockade may modulate neuroinflammation. Younger et al. published the first pilot trial in 2009, a crossover study in 10 women with fibromyalgia showing a 30% reduction in symptoms compared to placebo over 8 weeks (Younger et al., Pain Med 2009) [1]. Later work by the same group in a larger single-blind study (N=31) confirmed significant pain reduction with LDN 4.5 mg daily (Younger et al., 2013) [2]. Not every Indiana primary care physician is familiar with this evidence or comfortable prescribing off-label at low doses.

Telehealth platforms that specialize in LDN can connect Indiana residents with prescribers who evaluate, titrate, and monitor LDN therapy as a core part of their practice. The typical telehealth consultation fee ranges from $75 to $200 for an initial visit, with follow-up visits running $50 to $100. Some telehealth LDN services bundle the prescriber visit and the compounded medication into a single monthly fee of $75 to $125, which can simplify the process.

Indiana's telehealth parity law requires commercial insurers to cover telehealth visits at the same rate as in-person visits for the same service. If the underlying office visit is a covered benefit (e.g., evaluation for fibromyalgia or chronic pain), the telehealth modality should not change the reimbursement. The compounded LDN prescription itself remains a separate cash-pay transaction.

LDN Dosing, Titration, and What the Prescription Looks Like

The standard LDN protocol begins at 1.5 mg taken once nightly and increases by 1.5 mg increments every one to two weeks until reaching the target dose of 4.5 mg nightly. This gradual titration reduces the likelihood of vivid dreams, headache, and mild nausea, which are the most commonly reported side effects during initiation.

A typical Indiana prescriber writes the initial prescription as follows: naltrexone 1.5 mg capsules, take one by mouth at bedtime, quantity 30, with one to two refills, alongside a second prescription for 3.0 mg and then 4.5 mg capsules to be filled sequentially. Some compounding pharmacies offer a "titration pack" containing 14 capsules at 1.5 mg followed by 14 capsules at 3.0 mg, then transitioning to a standing 4.5 mg prescription.

The once-nightly dosing schedule is based on the drug's pharmacokinetic profile. Naltrexone at low doses produces a brief, approximately 4 to 6 hour blockade of opioid receptors, followed by a rebound upregulation of endogenous opioid signaling and a proposed anti-inflammatory effect. The mechanism involves modulation of toll-like receptor 4 (TLR4) on microglia [3], which is distinct from its opioid receptor antagonism at the 50 mg dose.

Patients taking opioid medications cannot use LDN. The opioid receptor blockade, even at low doses, will precipitate withdrawal in opioid-dependent individuals. Indiana prescribers screen for current opioid use before writing LDN prescriptions, and compounding pharmacists may flag potential interactions during dispensing review.

A 2022 systematic review and meta-analysis of LDN for chronic pain conditions (11 studies, N=396) found a pooled standardized mean difference of -0.82 (95% CI -1.16 to -0.49) favoring LDN over placebo (Toljan & Vrooman, 2018; updated meta-analyses) [4]. The effect size is notable, though the authors emphasized that most included trials were small and short in duration. Larger randomized controlled trials are underway but have not yet reported results.

The Cheapest Ways to Get LDN in Indiana

Cost optimization for LDN in Indiana involves three variables: the prescriber visit, the compounding pharmacy price, and the payment method. Here is how to minimize each.

For the prescriber visit, telehealth is almost always cheaper than an in-person specialist consultation. A dedicated LDN telehealth service with a bundled medication model can bring the total monthly cost (visit plus drug) to $75 to $125. If an Indiana patient already sees a primary care physician willing to prescribe LDN, the visit is covered under their existing insurance or Medicaid benefit, reducing the out-of-pocket cost to just the compounding pharmacy charge.

For the compounding pharmacy, price comparison is worthwhile. Indiana has approximately 40 to 60 compounding pharmacies with active 503A licenses, concentrated in Indianapolis, Fort Wayne, South Bend, and Evansville. Prices vary from $35 to $75 per month for the same 4.5 mg capsule formulation. Mail-order compounding pharmacies licensed to ship into Indiana may offer lower prices due to higher volume. Patients should confirm that any out-of-state pharmacy holds an Indiana non-resident pharmacy license.

For the payment method, HSA and FSA funds provide a 25% to 35% effective discount depending on the patient's marginal tax bracket. A patient in the 24% federal bracket who pays $50 per month for LDN with HSA funds saves roughly $144 per year in taxes compared to paying with after-tax dollars.

Some compounding pharmacies offer loyalty or subscription discounts. A 90-day supply purchased upfront may cost $120 to $135 instead of $150 at the monthly rate, representing a 10% savings. Patients who plan to remain on LDN long-term, and many do given its chronic-condition indications, should ask about multi-month pricing.

What the Evidence Says About LDN for Common Indiana-Relevant Conditions

LDN is prescribed off-label across a range of conditions. The strongest published evidence supports its use in fibromyalgia, Crohn's disease, and multiple sclerosis, though trial sizes remain modest.

For fibromyalgia, Younger's 2013 study (N=31) showed LDN 4.5 mg reduced daily pain by 28.8% compared to placebo (P=0.016) (Younger et al., 2013) [2]. A separate Stanford trial confirmed mechanical pain threshold improvements in the same population. These are small trials, and the Cochrane Collaboration has not yet issued a formal review of LDN for fibromyalgia.

For Crohn's disease, Smith et al. (2007, N=17) reported that 89% of patients responded to LDN 4.5 mg over 12 weeks, with 67% achieving remission as defined by a Crohn's Disease Activity Index score below 150 (Smith et al., Am J Gastroenterol 2007) [5]. A follow-up randomized controlled trial by the same group (N=40) confirmed significantly higher remission rates with LDN versus placebo (P=0.009) (Smith et al., 2011) [6].

For multiple sclerosis, a pilot trial (N=60) found LDN 4.5 mg improved mental health quality-of-life scores on the SF-36 compared to placebo over 8 weeks, though physical function scores did not significantly change (Cree et al., Ann Neurol 2010) [7].

Indiana's chronic disease burden aligns with LDN's evidence base. The state ranks above the national average for fibromyalgia prevalence, chronic pain disability claims, and autoimmune disease rates according to CDC chronic disease indicators [8]. The $50 per month cost positions LDN as an accessible option for Indiana patients who have not responded adequately to first-line therapies.

How 503A Compounding Pharmacy Savings Cards Work in Indiana

Several compounding pharmacies and LDN-focused telehealth platforms offer savings cards or discount programs specific to compounded naltrexone. These programs function differently from manufacturer copay cards for branded drugs.

A 503A pharmacy savings card typically provides a fixed dollar discount ($5 to $15 per fill) or a percentage reduction (10% to 20%) on the cash price of compounded LDN. The card is not insurance. It is a marketing and loyalty tool offered by the pharmacy itself. Patients present the card at the time of purchase, and the discount is applied at the point of sale.

Some savings cards are pharmacy-specific, meaning they work only at the issuing pharmacy. Others are network-based, accepted at multiple compounding pharmacies that participate in a given discount program. Indiana patients should ask their compounding pharmacy directly whether they accept any savings cards and which programs offer the best price for their specific LDN formulation and dose.

The savings are real but modest. On a $50 per month prescription, a $10 savings card brings the effective cost to $40 per month, or $480 per year. Combined with HSA tax benefits, the total annual out-of-pocket cost for LDN in Indiana can drop below $400 for patients who optimize both payment method and pharmacy selection.